Jpmorgan Chase & CO Chinook Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $2.35 Million - $4.86 Million	125,855 Added 79.67%	283,819 $10.9 Million
Q1 2023 May 18, 2023	BUY	$21.53 - $26.8 $1.31 Million - $1.63 Million	60,756 Added 62.5%	157,964 $3.66 Million
Q1 2023 May 11, 2023	SELL	$21.53 - $26.8 $1.18 Million - $1.47 Million	-54,777 Reduced 36.04%	97,208 $2.25 Million
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $3.07 Million - $4.51 Million	-164,846 Reduced 52.03%	151,985 $3.98 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $3.24 Million - $4.32 Million	184,955 Added 140.25%	316,831 $6.23 Million
Q2 2022 Aug 11, 2022	SELL	$12.59 - $18.8 $16,039 - $23,951	-1,274 Reduced 0.96%	131,876 $2.31 Million
Q1 2022 May 11, 2022	BUY	$12.02 - $16.69 $35,879 - $49,819	2,985 Added 2.29%	133,150 $2.18 Million
Q4 2021 Feb 10, 2022	SELL	$10.69 - $16.83 $11,908 - $18,748	-1,114 Reduced 0.85%	130,165 $2.12 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $1.51 Million - $1.95 Million	131,279 New	131,279 $1.68 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.